• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    9 Meters Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Events That Accelerate or Increase a Direct Financial Obligation, Bankruptcy or Receivership, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits

    7/18/23 8:00:11 AM ET
    $NMTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NMTR alert in real time by email

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): July 17, 2023

     

     

     

    9 Meters Biopharma, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-37797   27-3948465

    (State or other jurisdiction of

    incorporation or organization)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    4509 Creedmoor Road, Suite 600, Raleigh, NC 27612

    (Address of principal executive offices) (Zip Code)

     

    (919) 275-1933

    (Registrant’s telephone number, include area code)

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock $0.0001 Par Value NMTR The Nasdaq Stock Market LLC

     

     

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

    Item 1.01. Entry Into a Material Definitive Agreement.

     

    To the extent applicable, the information related to the Amendment set forth in Item 2.04 of this Current Report on Form 8-K is incorporated herein by reference.

     

    Item 1.03. Bankruptcy or Receivership.

    On July 17, 2023, after considering all strategic alternatives, 9 Meters Biopharma, Inc. (the “Company”), together with its subsidiaries, ceased operations and filed a voluntary petition for relief under provisions of Chapter 7 of Title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the Eastern District of North Carolina Case No. 23-01992-5-PWM (the “Bankruptcy Filing”). A Chapter 7 trustee will be appointed by the Bankruptcy Court and will assume control over the assets and liabilities of the Company, effectively eliminating the authority and powers of the Board of Directors of the Company and its executive officers to act on behalf of the Company. The assets of the Company will be liquidated and claims paid in accordance with the Bankruptcy Code.

     

    Item 2.04. Triggering Events that Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.

     

    The Bankruptcy Filing triggers events of default under all of the Company’s outstanding debt obligations, including the Company’s amended and restated senior secured convertible note, originally issued on July 15, 2022, which was subsequently amended and restated on November 7, 2022, and further amended on January 12, 2023 (the “Note”).

     

    As previously disclosed, on April 26, 2023, the Company entered into a forbearance agreement, which was subsequently amended on May 18, 2023 (the “Forbearance Agreement”), with the existing holder (the “Holder”) of the Company’s Note. On July 10, 2023, effective as of June 29, 2023, the Holder and the Company agreed to a second amendment to the Forbearance Agreement (the “Amendment”) to, among other things, extend the forbearance period until July 31, 2023 (the “Extended Forbearance Period”), deferring the July 1, 2023 payment pursuant to the Note during the Extended Forbearance Period (unless earlier terminated under the terms of the Amendment). In exchange for the Holder agreeing to enter into the Amendment, the Company agreed to a partial acceleration payment of approximately $1.08 million in cash from the Note reserve account, leaving approximately $1.6 million outstanding under the Note. However, under the terms of the Forbearance Agreement and the Note, the Extended Forbearance Period was terminated upon the Bankruptcy Filing.

     

    Except as set forth above, all other terms, conditions and rights of the Forbearance Agreement, the Note and the related Note transaction documents remain in full force and effect, which were described in the Current Report on Form 8-K filed by the Company on June 30, 2022, the Quarterly Report on Form 10-Q filed by the Company on November 8, 2022, the Current Report on Form 8-K filed by the Company on January 13, 2023, the Current Report on Form 8-K on April 27, 2023 and the Current Report on Form 8-K on May 19, 2023.

     

    The foregoing description of the Amendment does not purport to be complete and is subject to, and qualified by, the full text of such document, a copy of which is filed as Exhibit 10.1 and is incorporated by reference herein.

     

    Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

     

     

     

    On July 17, 2023, the Company received a letter from the staff of the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company and the Chapter 7 trustee that the Staff has, in accordance with Listing Rules 5101, 5110(b), and IM-5101-1, determined that the Company’s securities will be delisted from Nasdaq based on the following factors: (i) on July 17, 2023, the Company entered the Bankruptcy Filing and the associated public interest concerns raised by such filing; (ii) concerns regarding the residual equity interest of the existing listed securities holders; and (iii) concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq, including the Company’s failure to comply with (a) the minimum $2,500,000 stockholders’ equity requirement under Listing Rule 5550(b)(1) and (b) the minimum bid price requirement under Listing Rule 5550(a)(2), pursuant to the notice received by the Company from the Staff on March 31, 2023, which was disclosed in the Company’s Current Report on Form 8-K, dated April 6, 2023.

    The Staff’s letter indicates that the trading of the Company’s common stock will be suspended at the opening of business on July 26, 2023, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq.

    The Company does not intend to appeal the Staff’s determination. Therefore, the Company expects that the trading of the Company’s common stock will be suspended at the opening of business on July 26, 2023, and delisted from Nasdaq, as indicated in the Staff’s letter.

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Concurrent with the Bankruptcy Filing, on July 17, 2023, Bethany Sensenig, Interim Chief Executive Officer and Chief Financial Officer, tendered her resignation, effective July 17, 2023. As of July 17, 2023, the Company has no officers, consultants or employees.

     

    Concurrent with the Bankruptcy Filing, on July 17, 2023, directors Mark Sirgo (Chair), Michael Constantino, Lorin Johnson, Michael Rice and Samantha Ventimiglia resigned as members of the Company’s Board of Directors. The Company has no current members of the Board of Directors.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No. Description
    Exhibit 10.1 Amendment No. 2 to the Forbearance Agreement.
    Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

           
      9 Meters Biopharma, Inc.
           
    Date: July 18, 2023 By:   /s/ Bethany Sensenig
          Bethany Sensenig
          Chief Financial Officer

     

     

     

     

     

     

     

     

     

     

     

     

    false 0001551986 0001551986 2023-07-17 2023-07-17
    Get the next $NMTR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NMTR

    DatePrice TargetRatingAnalyst
    7/8/2021$5.00Outperform
    BMO Capital Markets
    More analyst ratings

    $NMTR
    Financials

    Live finance-specific insights

    See more
    • 9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022

      Positive final results from the vurolenatide Phase 2 VIBRANT study in short bowel syndrome (SBS) reaffirmed the efficacy and safety of vurolenatide and determined the Phase 3 dose and regimenClinical plans and activities are underway including site and patient recruitment to facilitate Phase 3 study initiation upon protocol finalization with FDA this quarterRALEIGH, NC / ACCESSWIRE / November 8, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the third quarter ended Septembe

      11/8/22 8:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022

      Positive preliminary results from Phase 2 VIBRANT study of vurolenatide in short bowel syndrome announcedVurolenatide End-of-Phase 2 meeting with FDA on track for 3QCash balance as of June 30, 2022 of $29.5 million; additional $20 million from previously announced July debt financing extends cash runway into 4Q 2023RALEIGH, NC / ACCESSWIRE / August 15, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the second quarter ended June 30, 2022.John Temperato, President & Chief Exe

      8/15/22 7:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022

      On track to report Phase 2 data for vurolenatide for short bowel syndrome and Phase 3 interim analysis for celiac disease in JuneCash balance as of March 31, 2022, of $37.2 million is expected to fund ongoing clinical programs and business operations into Q2 2023RALEIGH, NC / ACCESSWIRE / May 16, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the first quarter ended March 31, 2022.John Temperato, President & Chief Executive Officer of 9 Meters Biopharma, commented: "This is

      5/16/22 7:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NMTR
    SEC Filings

    See more
    • SEC Form 25-NSE filed by 9 Meters Biopharma Inc.

      25-NSE - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      9/8/23 10:11:45 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by 9 Meters Biopharma Inc.

      144 - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      7/19/23 4:41:57 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Events That Accelerate or Increase a Direct Financial Obligation, Bankruptcy or Receivership, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits

      8-K - 9 METERS BIOPHARMA, INC. (0001551986) (Filer)

      7/18/23 8:00:11 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NMTR
    Leadership Updates

    Live Leadership Updates

    See more

    $NMTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $NMTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $NMTR
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $NMTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer

      Corium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years' experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"), a commercial-stage specialty pharmaceutical company focused on pain and addiction management. During his tenure at BDSI,

      1/17/23 8:00:00 AM ET
      $AGRX
      $GNTA
      $NMTR
      $PG
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Package Goods/Cosmetics
    • 9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer

      Formerly served as VP of Finance and Commercial Operations at Biogen with 20+ years of business and strategic financial leadership experienceRALEIGH, NC / ACCESSWIRE / January 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases announced today the Company has appointed Bethany Sensenig, MBA, CMA, as Chief Financial Officer."We're very pleased to have Ms. Sensenig join the 9 Meters team as Chief Financial Officer with over twenty years of business and strategic financial leadership experience at both early-stage and large biotechnology companies," said John Temperato, President & Chief

      1/18/22 8:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor Relations & Corporate Communications

      RALEIGH, NC / ACCESSWIRE / January 3, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR),a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today the Company has appointed Sarah Liu, MBA, as Chief Commercial Officer and Al Medwar, MBA, as Senior Vice President, Investor Relations & Corporate Communications."We are very excited to have such talented individuals, each with lengthy and accomplished pharmaceutical and biotech backgrounds, join the 9 Meters team during this critical time of growth for our company," said John Temperato, President & Chief Executive Officer of 9 Meters Biopharma. "Ms. Liu's

      1/3/22 7:30:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Sensenig Bethany

      4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)

      4/21/23 5:08:33 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Sirgo Mark A

      4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)

      3/31/23 4:35:29 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Rice Yehuda Michael

      4 - 9 METERS BIOPHARMA, INC. (0001551986) (Issuer)

      3/31/23 4:28:24 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BMO Capital Markets initiated coverage on 9 Meters Biopharma with a new price target

      BMO Capital Markets initiated coverage of 9 Meters Biopharma with a rating of Outperform and set a new price target of $5.00

      7/8/21 7:33:42 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on 9 Meters Biopharma with a new price target

      Citigroup initiated coverage of 9 Meters Biopharma with a rating of Buy and set a new price target of $3.00

      6/4/21 7:33:28 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Brookline Capital resumed coverage on 9 Meters Biopharma with a new price target

      Brookline Capital resumed coverage of 9 Meters Biopharma with a rating of Buy and set a new price target of $6.00

      3/25/21 11:52:35 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome

      RALEIGH, NC / ACCESSWIRE / May 30, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the Board of Directors has accepted the resignation of John Temperato as President and Chief Executive Officer of the Company effective immediately.Mark Sirgo, Chairman of the Board of 9 Meters, stated, "On behalf of the Board of Directors, I want to thank John for his service and dedication to the Company." The Board of Directors has appointed Bethany Sensenig, Chief Financial Officer of 9 Meters, to serve as interim Chief Executive Officer in addition to her current responsibiliti

      5/30/23 9:25:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023

      RALEIGH, NC / ACCESSWIRE / May 15, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023.John Temperato, President & Chief Executive Officer of 9 Meters Biopharma, commented: "We are enthusiastic about the potential of vurolenatide and NM-136 to deliver value to patients. We are exploring options to fund further advancement of these assets, including financing and other strategic alternatives."Clinical Development and Business HighlightsPresentations on vurolenatide and SBS at ASPEN 2

      5/15/23 5:15:00 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity

      RALEIGH, NC / ACCESSWIRE / April 5, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced receipt of a written response from the U.S. Food and Drug Administration (FDA) on the request for a Type B pre-IND (Investigational New Drug) meeting on the planned pre-clinical development of NM-136 for the treatment of obesity. Based on the response, the Company currently plans to submit an IND to the FDA for this indication in the second half of 2023 based on the completion of the preclinical program. An approved IND is a prerequisite for conducting Phase 1 clinical studies of NM-136

      4/5/23 8:00:00 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by 9 Meters Biopharma Inc. (Amendment)

      SC 13G/A - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      2/7/24 7:40:26 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by 9 Meters Biopharma Inc. (Amendment)

      SC 13G/A - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      2/9/23 11:51:13 AM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by 9 Meters Biopharma Inc.

      SC 13G - 9 METERS BIOPHARMA, INC. (0001551986) (Subject)

      7/8/22 4:57:05 PM ET
      $NMTR
      Biotechnology: Pharmaceutical Preparations
      Health Care